APPENDIX C 
ABSTRACT OF PROTOCOL 
Melanoma and renal cell cancer patients with advanced cancer who have failed standard 
therapy will receive treatment with tumor infiltrating lymphocytes (TIL), Peripheral Blood 
Lymphocytes (PBL), and cytokines. TIL cells will either consist of a bulk population or TIL 
cells that have been enriched either for the CD4 or CD8 marker. The effector cells will be 
exposed to retroviral vector containing supernatant for the purpose of marking a portion of the 
effector cells. Each patient will be infused with two populations of effector cells, each 
population marked with a different retroviral vector. The marked cells can be detected by the 
presence of the gene inserted by the retroviral vector. At various times after administration of 
the TIL to the patient, samples of blood, lymph nodes, and tumor will be obtained and tested 
for the presence of marked cells. The gene marked cells will be used to evaluate the survival 
and trafficking of the infused cells. The information obtained will determine if TIL exhibit 
unique properties different from circulating T cells that enable them to selectively traffic to 
tumor deposits. 
Recombinant DNA Research, Volume 15 
[565] 
